Cipher Pharmaceuticals Inc.

You are currently on hold for this Cypher Pharmaceuticals first quarter 2022 results conference call. At this time, we are assembling today's audience and plan to be underway shortly. We appreciate your patience and please remain on the line.

Thank you. Thank you.

Good morning, ladies and gentlemen, thank you for standing by. Welcome to the cipher pharmaceuticals. 1st, quarter 2022 results conference call at this time. All participants are in a listen only mode following today's presentation instructions will be given for the question and answer session. If anyone needs assistance at any time during the call, you may press the star followed by the 0 on your push button phone. As a reminder, this conference is being recorded today, Friday, May 13th, 2022. On behalf of the speakers that follow, listeners are cautioned that today's presentation and the responses to questions may contain forward-looking statements within the meaning of the safe harbor provisions of the Canadian Provincial Securities Laws. Forward-looking statements involve risks and uncertainties and undue reliance should not be placed on such statements. Certain material factors or assumptions are implied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements. For additional information about factors that could cause results to vary, please refer to the risks identified in the company's annual information form and other filings with Canadian regulatory authorities. Except as required by Canadian securities laws, the company does not undertake to update any forward-looking statements. Such statements speak only as of the date made. I would now like to turn the call over to Mr. Craig Moll, Interim Chief Executive Officer of the company. Please go ahead, Mr. Moll.